Parameter | Cutoff | Univariate | Multivariate | |
---|---|---|---|---|
P | HR (95 % CI) | P | ||
Age | ≥65 years vs <65 years† | 0.2151 | ||
Initial PSA | ≥20 ng/mL vs <20 ng/mL | 0.9923 | ||
Pathological T stage | ≥T3 vs ≤ T2 | 0.5521 | ||
Pathological GS | ≥8 vs ≤7 | 0.0558 | ||
Gleason pattern 5 | Yes vs no | 0.0004* | 4.166 (1.351 to 12.76) | 0.0133* |
Extraprostatic extension | Yes vs no | 0.4370 | ||
Lymphovascular invasion | Yes vs no | 0.0101* | 1.005 (0.323 to 3.130) | 0.9935 |
Positive surgical margin | Yes vs no | 0.2967 | ||
Seminal vesicle invasion | Yes vs no | 0.1506 | ||
Perineural invasion | Yes vs no | 0.0157* | 5.876 (1.139 to 107.5) | 0.0316* |
Timing of SRT | ueSRT vs eSRT vs dSRT | 0.0364* | – | –‡ |
ueSRT + eSRT vs dSRT | 0.0108* | 3.117 (1.141 to 7.880) | 0.0280* | |
ueSRT vs eSRT + dSRT | 0.2991 | |||
SRT technique | 3DCRT vs IMRT | 0.4964 | ||
Total dose | ≥66 Gy vs <66 Gy | 0.6278 | ||
Concomitant ADT | Yes vs no | 0.3118 | ||
PSA doubling time | ≥6 months vs <6 months | 0.0071* | – | –‡ |